EQL Share Price Performance
SEK 26.00
-61.00 (-70.11%)
69.9% undervalued intrinsic discount
SEK 86.37
Fair Value
Price SEK 26.00
Mandelman SEK 86.37
AnalystConsensusTarget SEK 75.00
Fair ValueSEK 86.37
Share Pricen/a
Analysis Article • May 14
EQL Pharma AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
EQL Community Narratives
MA
Fair Value
·Fair Value SEK 86.37 69.9% undervalued intrinsic discount
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
2users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value
·Fair Value SEK 75 65.3% undervalued intrinsic discount
European Market Expansion And Pipeline Development Will Unlock Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
EQL Pharma is pushing hard to expand its range of everyday medicines, with a growing lineup of new products that could keep sales climbing fast. The catch is that the shares already reflect a lot of optimism, and execution plus cash flow need to keep up for the story to work.Read more
MA
SEK 86.37
69.9% undervalued intrinsic discount
Fair Value
Revenue
21.49% p.a.
Profit Margin
15%
Future PE
25x
Price in 2029
SEK 115.56
European Market Expansion And Pipeline Development Will Unlock Potential
Key Takeaways Enlarged European market reach and a deep pipeline of generics underpin prospects for robust, sustained revenue and margin growth. Operational efficiencies, disciplined acquisitions, and targeted R&D boost earnings quality and position EQL Pharma for enhanced resilience and market value.Read more
AN
SEK 75
65.3% undervalued intrinsic discount
Fair Value
Revenue
26.96% p.a.
Profit Margin
16.91%
Future PE
17.79x
Price in 2029
SEK 84.63
Trending Discussion
Recently Updated Narratives
MA
EQL Pharma's management aiming for 30% Revenue Growth in 5 Years
Fair Value: SEK 86.37 69.9% undervalued intrinsic discount
18 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
EQL: Italian Approval And New Market Entry Will Support Future Upside Potential
Fair Value: SEK 75 65.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
EQL Pharma AB (publ) Key Details
About EQL
- Founded
- 2006
- Employees
- 55
- CEO
- WebsiteView website
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
